Potential Oncogenic and Immunosuppressive Roles of Multiple EGF-Like Domains 6 (MEGF6) in Colon Cancer: Insights from Bioinformatic Analysis
DOI:
https://doi.org/10.48048/tis.2024.8290Keywords:
MEGF6, Colon cancer, Prognosis, Biomarker, Immunomodulation, BioinformaticsAbstract
Multiple epidermal growth factor-like domains protein 6 (MEGF6) is a high molecular weight protein with several EGF-like domains. Although it has been demonstrated to promote metastasis and chemoresistance in colon cancer cells, its specific oncogenic and immunologic functions remain largely unexplored. This study aims to comprehensively analyze publicly available datasets to define the role of MEGF6 in colon cancer development and immune response modulation. The expression of MEGF6 in colon adenocarcinoma (COAD) and normal tissues at both mRNA and protein levels was assessed using the GEPIA2 and HPA databases, respectively. The UALCAN database was employed to examine the association between MEGF6 expression and clinicopathological outcomes in COAD patients, and survival analysis was conducted using the KM plotter database. Functional enrichment analysis of MEGF6-correlated genes was performed using the ShinyGO online tool. Additionally, the correlation of MEGF6 with immune cell infiltration and immunosuppressive molecules was explored through the TIMER and TISIDB databases. Our analysis revealed significantly higher mRNA and protein expressions of MEGF6 in COAD tissues compared to normal tissues, with associations to cancer stage, nodal metastasis status, and histological subtype. High MEGF6 expression was correlated with poorer survival outcomes, and genes correlated with MEGF6 were enriched in biological processes related to cellular component organization, cell adhesion, and extracellular matrix interaction. Furthermore, MEGF6 expression demonstrated a significant correlation with immune cell infiltration and the expression of immunosuppressive molecules, particularly CTLA-4, PD-1, PD-L1, TGF-β, and IL-10. In conclusion, our findings suggest that MEGF6 may play an oncogenic role by influencing cell and extracellular matrix interactions. Its overexpression may indicate immunosuppressive properties within the cancer microenvironment. Therefore, MEGF6 holds promise as a potential biomarker for predicting both prognosis and therapeutic responses in colon cancer.
HIGHLIGHTS
- MEGF6 has been shown to involve colon cancer growth and chemotherapeutic resistance.
- Bioinformatics confirmed a prognostic significance of MEGF6 in colon cancer.
- MEGF6 may exert its oncogenic effects by influencing cell-matrix interactions.
- MEGF6 expression is correlated with immunosuppressive properties of cancers.
GRAPHICAL ABSTRACT
Downloads
References
E Dekker, PJ Tanis, JLA Vleugels, PM Kasi and MB Wallace. Colorectal cancer. Lancet 2019; 394, 1467-80.
F Bray, M Laversanne, H Sung, J Ferlay, RL Siegel, I Soerjomataram and A Jemal. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024; 74, 229-63.
C Zeng, W Wen, AK Morgans, W Pao, XO Shu and W Zheng. Disparities by race, age, and sex in the improvement of survival for major cancers: Results from the national cancer institute surveillance, epidemiology, and end results (SEER) program in the United States, 1990 to 2010. JAMA Oncol. 2015; 1, 88-96.
H Brenner, M Kloor and CP Pox. Colorectal cancer. Lancet 2014; 383, 1490-502.
M Arnold, MS Sierra, M Laversanne, I Soerjomataram, A Jemal and F Bray. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017; 66, 683-91.
Y Wang, H Song, W Wang and Z Zhang. Generation and characterization of Megf6 null and Cre knock-in alleles. Genesis 2019; 57, e23262.
CC Teerlink, MJ Jurynec, R Hernandez, J Stevens, DC Hughes, CP Brunker, K Rowe, DJ Grunwald, JC Facelli and LA Cannon-Albright. A role for the MEGF6 gene in predisposition to osteoporosis. Ann Hum. Genet. 2021; 85, 58-72.
L Dorstyn, E Hackett-Jones, A Nikolic, MD Norris, Y Lim, J Toubia, M Haber and S Kumar. Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling. Cell Death Dis. 2019; 10, 56.
H Hu, M Wang, H Wang, Z Liu, X Guan, R Yang, R Huang, Q Tang, C Zou, G Wang, X Gao and X Wang. MEGF6 promotes the epithelial-to-mesenchymal transition via the TGFβ/SMAD signaling pathway in colorectal cancer metastasis. Cell Physiol. Biochem. 2018; 46, 1895-906.
Y Mou, N He, M Su, Z Zhong, J Ma, J Liu, X Cheng and P Dai. MiR-1254 and MEGF6 regulates oxaliplatin resistance in human colorectal cancer cells. Am. J. Transl. Res. 2021; 13, 183-96.
M Herrera, A Berral-González, I López-Cade, C Galindo-Pumariño, S Bueno-Fortes, M Martín-Merino, A Carrato, A Ocaña, CDL Pinta, A López-Alfonso, C Peña, V García-Barberán and JDL Rivas. Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. Mol. Cancer 2021; 20, 73.
A Banerjee, Y Chabria, NRR Kanna, J Gopi, P Rowlo, XF Sun and S Pathak. Role of tumor specific niche in colon cancer progression and emerging therapies by targeting tumor microenvironment. Adv. Exp. Med. Biol. 2021; 1341, 177-92.
M Schmitt and FR Greten. The inflammatory pathogenesis of colorectal cancer. Nat. Rev. Immunol. 2021; 21, 653-67.
H Ruan, BJ Leibowitz, L Zhang and J Yu. Immunogenic cell death in colon cancer prevention and therapy. Mol. Carcinog. 2020; 59, 783-93.
X Yang, W Wu, Y Pan, Q Zhou, J Xu and S Han. Immune-related genes in tumor-specific CD4(+) and CD8(+) T cells in colon cancer. BMC Cancer 2020; 20, 585.
R Ogawa, T Yamamoto, H Hirai, K Hanada, Y Kiyasu, G Nishikawa, R Mizuno, S Inamoto, Y Itatani, Y Sakai and K Kawada. Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via the CXCL1/8-CXCR2 axis. Clin. Cancer Res. 2019; 25, 2887-99.
W Huang, D Su, X Liao, T Yang, Y Lu and Z Zhang. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer. Sci. Rep. 2023; 13, 789.
K Somsuan and S Aluksanasuwan. Bioinformatic analyses reveal the prognostic significance and potential role of ankyrin 3 (ANK3) in kidney renal clear cell carcinoma. Genomics Inform. 2023; 21, e22.
S Aluksanasuwan, K Somsuan, J Ngoenkam, S Chutipongtanate and S Pongcharoen. Potential association of HSPD1 with dysregulations in ribosome biogenesis and immune cell infiltration in lung adenocarcinoma: An integrated bioinformatic approach. Cancer Biomark. 2024; 39, 155-70.
C Chen, S Aluksanasuwan and K Somsuan. Expression of anoctamin 7 (ANO7) is associated with poor prognosis and mucin 2 (MUC2) in colon adenocarcinoma: A study based on TCGA data. Genomics Inform. 2023; 21, e46.
Z Tang, B Kang, C Li, T Chen and Z Zhang. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic. Acids Res. 2019; 47, W556-W560.
F Pontén, K Jirström and M Uhlen. The human protein atlas - a tool for pathology. J. Pathol. 2008; 216, 387-93.
M Uhlén, L Fagerberg, BM Hallström, C Lindskog, P Oksvold, A Mardinoglu, Å Sivertsson, C Kampf, E Sjöstedt, A Asplund, IM Olsson, K Edlund, E Lundberg, S Navani, CAK Szigyarto, J Odeberg, D Djureinovic, JO Takanen, S Hober, T Alm, …, F Pontén. Proteomics. Tissue-based map of the human proteome. Science 2015; 347, 1260419.
DS Chandrashekar, B Bashel, SAH Balasubramanya, CJ Creighton, I Ponce-Rodriguez, BVSK Chakravarthi and S Varambally. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017; 19, 649-58.
A Lánczky, B Győrffy. Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation. J. Med. Internet. Res. 2021; 23, e27633.
SX Ge, D Jung and R Yao. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics 2020; 36, 2628-9.
T Li, J Fan, B Wang, N Traugh, Q Chen, JS Liu, B Li and XS Liu. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017; 77, e108-e110.
B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, JC Aster, S Rodig, S Signoretti, JS Liu and XS Liu. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17, 174.
B Ru, CN Wong, Y Tong, JY Zhong, SSW Zhong, WC Wu, KC Chu, CY Wong, CY Lau, I Chen, NW Chan and J Zhang. TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics 2019; 35, 4200-2.
N Tejeda-Muñoz and KC Mei. Wnt signaling in cell adhesion, development, and colon cancer. IUBMB Life 2024; 76, 383-96.
H Zhao, T Ming, S Tang, S Ren, H Yang, M Liu, Q Tao and H Xu. Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target. Mol. Cancer 2022; 21, 144.
D Zhou, J Fan, Z Liu, R Tang, X Wang, H Bo, F Zhu, X Zhao, Z Huang, L Xing, K Tao, H Zhang, H Nie, H Zhang, W Zhu, Z He and L Fan. TCF3 regulates the proliferation and apoptosis of human spermatogonial stem cells by targeting PODXL. Front. Cell Dev. Biol. 2021; 9, 695545.
Y Zhang, W Sime, M Juhas and A Sjölander. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur. J. Cancer 2013; 49, 3320-34.
H Liang, G Liu, W Zeng, Q Fan, Z Nie, H Hu, R Zhang and S Xie. MEGF6 prevents sepsis-induced acute lung injury in mice. Int. Immunopharmacol. 2023; 123, 110727.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
